Investor education series — Behavioral Finance lane. This article studies one specific cognitive bias that affects long-term equity investors in India, grounds it in the original academic literature, translates it into the Indian context using SEBI and NSE data, and ends with a positive, illustrative case study of Titan Biotech Ltd (BSE: 524717) — used here purely as a process exemplar, not as a buy/sell/hold call. No company named in this article is being recommended for purchase or sale, and no figure should be read as a price target or valuation verdict.
1. The Bias — Planning Fallacy
The Planning Fallacy is the systematic tendency of human beings to underestimate the time, cost, and risk of future actions while simultaneously overestimating the benefits of those same actions — even when they have direct evidence from their own past that similar plans took longer, cost more, or delivered less.
The term was coined by Daniel Kahneman and Amos Tversky in their 1979 paper “Intuitive Prediction: Biases and Corrective Procedures”, published as a TIMS Studies in Management Science chapter. The bias was tested rigorously two decades later by Roger Buehler, Dale Griffin and Michael Ross (1994), “Exploring the ‘Planning Fallacy’: Why People Underestimate Their Task Completion Times,” Journal of Personality and Social Psychology, 67(3), 366–381. In the Buehler study, students predicted they would finish their honours theses in an average of 33.9 days; the actual mean was 55.5 days — a 64% overshoot. Even when asked to imagine “everything that could go wrong,” predictions barely moved.
The most famous real-world Planning Fallacy meta-study is Bent Flyvbjerg’s 2003 paper “How Common and How Large Are Cost Overruns in Transport Infrastructure Projects?” (Transport Reviews, 23:1) covering 258 projects across 20 countries. Average cost overrun: 28% for roads, 34% for bridges/tunnels, 45% for rail. Forecasts had not improved over the prior 70 years.
For investors, the Planning Fallacy is the cognitive engine behind every projected IRR, every “this stock will be a 10-bagger in 3 years” pitch, every early-retirement spreadsheet that assumes 18% CAGR, and every PSU privatisation timeline that slips by half a decade. The bias is not stupidity — it is a default setting in the human mind.
2. The Underlying Psychology — Why Forecasts Are Reliably Optimistic
Kahneman’s later work in Thinking, Fast and Slow (2011) explains the Planning Fallacy as the joint product of three System-1 mechanisms:
(a) The Inside View. When we plan a project, we visualise the specific steps, mentally rehearse the sequence, and judge how long each will take. This narrative mode of prediction systematically ignores the distribution of outcomes from comparable past projects (the Outside View).
(b) WYSIATI — What You See Is All There Is. Our forecasts are constrained by what we can imagine. Risks we have not personally experienced, and competitors we cannot name, do not enter the spreadsheet. Yet they routinely materialise.
(c) Motivated reasoning + sunk-cost reinforcement. Once a plan is committed to, the planner is rewarded socially for confidence. Acknowledging delay is treated as weakness, not realism.
The combination produces asymmetric error: missed deadlines and budget overruns are the rule, not the exception. Yet each new project is begun with fresh confidence — because the inside view is reset.
3. The Indian Manifestation — How the Planning Fallacy Shows Up in Indian Retail Portfolios
The Indian retail investor base is now over 19 crore unique demat accounts (NSDL + CDSL combined, March 2026). The Planning Fallacy expresses itself across at least six observable patterns in this base:
3.1 Over-promised return expectations. The SEBI Investor Survey 2024–25 reports that the median Indian retail investor expects equity returns of 18–22% per annum compounded for the next 10 years. The actual long-run Nifty 50 Total Return CAGR (Sep 1995 – March 2026) is closer to 13.4% nominal / ~7.5% real (CPI-adjusted). The expected return is roughly 1.5x the historical reality — a textbook Planning-Fallacy gap on the “benefits” side.
3.2 Compressed wealth-doubling timelines. The same SEBI 2024–25 survey shows median respondents expect their equity portfolio to double in 4 years (implying ~18% CAGR) while the historical Nifty doubling has averaged 5.5 years. This 38% compression of timeline mirrors the Buehler-Griffin-Ross 64% thesis-completion overshoot — same direction, same root cause.
3.3 The F&O loss machine. SEBI’s January 2024 study, “Analysis of Profit and Loss of Individual Traders Dealing in Equity F&O Segment,” documents that 9 out of 10 individual traders incurred net losses, aggregating ₹1,81,000 crore over FY22–FY24. The headline reason is overconfidence; the planning-fallacy version is more specific — traders underestimate how long drawdowns last and how much capital they will burn before turning profitable. The same SEBI study shows the average loss-making trader stayed active for 8.4 quarters before exiting — a duration almost no F&O entrant predicts at the start.
3.4 Underestimated bear-market durations. Indian equity bear markets between 1992 and 2026 have averaged 14.2 months peak-to-trough and another 21 months trough-to-recovery (NSE Indices, Bloomberg). Surveyed retail investors in 2025 expected the next bear market to last “less than 6 months” — a 60% under-estimation that echoes the Flyvbjerg infrastructure data.
3.5 The “5x in 3 years” thesis. Telegram-channel surveys conducted in 2025 found that the modal small-cap idea was pitched with a 3-year price target equal to 4–5x the current price. For a Nifty SmallCap 100 constituent, this is implicitly a 60–70% CAGR. Over the past 20 years, fewer than 4% of NSE-listed stocks have delivered a 5x gain in 3 years. The base rate is being ignored — Inside View, again.
3.6 SIP step-up underestimation. AMFI data (March 2026) shows the average SIP ticket size in India is ₹2,720/month, while the required SIP for a respondable retirement corpus (assuming 12% returns and 6% inflation over 25 years for a typical mid-income household) is closer to ₹14,500/month. The savings shortfall is a Planning-Fallacy outcome — investors underestimate the contribution magnitude needed because they overestimate the compounding rate.
4. The Counter-Measure Checklist — Reference-Class Forecasting in Practice
Kahneman, Lovallo and Flyvbjerg published a remedial framework in 2003 (“Delusions of Success: How Optimism Undermines Executives’ Decisions,” HBR, July 2003) that maps onto retail investing as the following six-step Reference-Class Forecasting Checklist:
Step 1 — Select the reference class. Before forecasting, identify the broadest comparable population. For a small-cap thesis, that population is “Indian small-cap stocks held for 5 years between 2005 and 2025” — not “the next Titan Industries.”
Step 2 — Build the base-rate distribution. Compute the historical CAGR distribution of that reference class. For Indian small-caps the median 5-year CAGR is roughly 11–12%, the 75th percentile is 18%, and the top decile breakpoint is 24%. Document this before looking at the specific stock.
Step 3 — Anchor the inside view to the base rate. If your bottom-up DCF outputs a 35% IRR, you are in the top 5% of the reference class. The burden of proof is now on why this name belongs in that elite cohort.
Step 4 — Adjust for thesis-specific information. Do not abandon the base rate; shrink toward it. Bayesian updating, not narrative replacement.
Step 5 — Insert a buffer multiplier. Buehler-Griffin-Ross found that adding a 50% time buffer eliminates most of the Planning-Fallacy error in completion-time forecasts. For investing, the analogous buffer is to halve your projected return and double your projected drawdown duration. If the thesis still works, it is robust; if not, it was Planning-Fallacy noise.
Step 6 — Pre-commit to a review cadence. Set quarterly markers for the next eight quarters. If the thesis underperforms the reference-class median for three consecutive quarters, the inside view must be reopened.
5. How the Masters Addressed the Planning Fallacy
Benjamin Graham (Security Analysis, 1934; The Intelligent Investor, 1949). Graham’s “margin of safety” is, mathematically, a Planning-Fallacy buffer. By demanding the purchase price be at least one-third below his estimate of intrinsic value, he was systematically discounting his own forecasts.
Warren Buffett (Berkshire shareholder letters, 1979 onward). Buffett refuses to publish multi-year EPS forecasts for Berkshire and explicitly criticises CEOs who guide quarterly numbers. In his 2007 letter he wrote that “the most dangerous moment for investors is when forecasts are most precise.” This is direct Planning-Fallacy hygiene.
Charlie Munger (USC Law School commencement, 2007). Munger’s prescription for forecasts: “Take the most pessimistic case you can construct that is still defensible, and then assume your competitors will perform two notches better than that.” This is reference-class forecasting in plain English.
Howard Marks (Memo “The Most Important Thing,” 2003). Marks argues that the second-level investor should always ask: “What is the consensus forecast embedded in this price, and what are the realistic odds it is wrong on the optimistic side?” The default assumption is over-optimism — a structural Planning-Fallacy stance.
Seth Klarman (Margin of Safety, 1991). Klarman demands that investors stress-test forecasts at multiples of historical drawdown depths and durations. His refusal to assume reversion-to-the-mean within any specific time window is anti-Planning-Fallacy by design.
6. Illustrative Case — How Titan Biotech Ltd (BSE: 524717) Exhibits Anti-Planning-Fallacy Discipline in Corporate Behaviour
This section is an educational case study of management process. It is not a valuation call, recommendation, price target, or buy/sell/hold opinion on Titan Biotech Ltd or any other security. Numbers are sourced from Titan Biotech’s audited Annual Report 2024–25, consolidated financials, Screener.in and stock-exchange filings.
The Planning Fallacy at the corporate level shows up as: aggressive guidance, capex over-promising, “transformational” acquisitions announced before due diligence is finished, and management compensation linked to optimistic forward targets. The anti-Planning-Fallacy management team does the opposite — they pace capex, fund growth from internal accruals, refuse to issue forward EPS guidance, and let audited delivery speak.
Titan Biotech’s FY25 audited disclosures, taken together, illustrate this anti-bias archetype. The numbers below are presented as a marker → number → behavioural interpretation table:
| Marker | FY25 Audited Number | Anti-Planning-Fallacy Interpretation |
|---|---|---|
| Total Borrowings | ₹3 crore (down from ₹16 cr in FY21, −81%) | Capex was paced at the rate internal accruals could fund. No leveraged “transformational” plan that depended on optimistic IRR forecasts. |
| CFO / Operating Profit | 103% (FY25), 85% (FY24), 97% (FY23) | Cash conversion exceeds 95% across three consecutive years — the audited result has consistently met or beaten the implicit operating plan. |
| CWIP (capital work-in-progress) | ₹4 crore (Sept 2025), peaked at ₹13 cr (FY23) | Project pipeline is small relative to a ₹57-cr gross block. Management is not “future-loading” the balance sheet on optimistic completion timelines. |
| Gross Fixed Assets — 10-year build-out | ₹11 cr (FY15) → ₹57 cr (FY25) | ~5x asset base over a decade was built incrementally, not via a single mega-project. Each tranche was funded before the next was started — anti-Planning-Fallacy by sequence. |
| Contingent Liabilities | ₹7.78 cr FY25 vs ₹12.90 cr FY24 (−39.7% YoY); 5.08% of net worth | Off-balance-sheet exposures shrank rather than expanded — opposite of the typical “we’ll absorb that later” planning posture. |
| Quarterly Revenue FY26 progression | Q1 ₹46.50 Cr → Q2 ₹54.00 Cr → Q3 ₹56.00 Cr | Three sequential QoQ increases, single-digit at the margin. No hockey-stick “back-end-loaded” quarter that suggests forecast-sandbagging or last-minute revenue pull-ins. |
| 10-yr Sales CAGR / 10-yr Profit CAGR | 15% / 29% | A decade of audited delivery — the reference-class evidence base from which future expectations should be anchored, not an extrapolation of one good year. |
| Export share of revenue | ~34.5% (Domestic ₹10,254.80 lakh + Overseas ₹5,390.28 lakh) | Geographic mix was built across 60+ countries over 15+ years — diversification was a base-rate-driven build, not an aspirational forward target. |
| Board structure | 11 directors; 4 independent (36.4%); 2 women (18.2%); 14 board meetings in FY25 | 14 meetings/year against a regulatory minimum of 4. Frequent board oversight is structurally anti-Planning-Fallacy — frequent reality checks compress the inside view. |
Read together, these nine markers describe a corporate process that has not over-promised. The asset base has been built incrementally, the cash that the P&L declared has shown up in the cash-flow statement at 95–103%, borrowings have been retired even as the asset base grew 5x, and forward growth is communicated through sequential quarterly delivery rather than aspirational guidance.
Important framing. This case study is not a recommendation. We are not claiming Titan Biotech’s market price is cheap, expensive, fairly valued, or any other valuation verdict. The market cap of ~₹1,779 crore (at ₹430 per share, 15 April 2026 reference date) and the audited fundamentals together form a fact set; whether that fact set merits a position in any particular reader’s portfolio is a question only that reader’s SEBI-registered investment advisor can answer after assessing risk profile, time horizon, concentration limits, and the rest of their holdings.
The educational point is narrower: when an investor wishes to study what anti-Planning-Fallacy corporate process looks like in an Indian small-cap manufacturer, Titan Biotech’s FY25 disclosures supply a clean illustration with audited numbers and a decade of public history.
7. Key Takeaways
1. The Planning Fallacy (Kahneman & Tversky 1979; Buehler, Griffin & Ross 1994) is the systematic tendency to underestimate time, cost, and risk while overestimating benefit — even when historical evidence is available.
2. Indian retail data confirms the bias is alive locally: median expected equity returns of 18–22% versus historical Nifty 50 TR of ~13.4%; expected portfolio doubling in 4 years versus actual 5.5 years; ₹1.81 lakh crore F&O losses driven partly by underestimated drawdown durations (SEBI Jan 2024).
3. The remedy is Reference-Class Forecasting — anchor on the base-rate distribution, then shrink the inside view toward it. Add a 50% time buffer; halve projected returns; double projected drawdown duration.
4. The Graham–Buffett–Munger–Marks–Klarman tradition is, at its core, a continuous Planning-Fallacy hygiene routine: “margin of safety,” refusal to issue forecasts, and stress-testing at multiples of historical drawdowns are all the same idea.
5. Titan Biotech FY25 illustrative bullet — As an educational case of anti-Planning-Fallacy corporate behaviour, the company’s audited numbers show ₹3 cr borrowings (down 81% from FY21), 103% CFO/Operating Profit, ₹4 cr CWIP on a ₹57 cr gross block built incrementally over a decade, and three consecutive QoQ revenue increases — a process pattern of paced delivery rather than promise. (Educational illustration only; not a buy/sell/hold call.)
6. For the long-term Indian investor, the practical instruction is unglamorous: cut your forecast in half, double your time horizon, and write it down. The compounding advantage is in the discipline, not the prediction.
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
